10-Q 1 dhc-20230930.htm 10-Q dhc-20230930
0001075415false12/312023Q3http://fasb.org/us-gaap/2023#OtherAssetshttp://fasb.org/us-gaap/2023#OtherAssetshttp://fasb.org/us-gaap/2023#OtherLiabilitieshttp://fasb.org/us-gaap/2023#OtherLiabilities00010754152023-01-012023-09-300001075415dhc:SeniorNotesDue2042Member2023-01-012023-09-300001075415dhc:SeniorNotesDue2046Member2023-01-012023-09-3000010754152023-10-27xbrli:shares00010754152023-09-30iso4217:USD00010754152022-12-31iso4217:USDxbrli:shares0001075415dhc:RentalIncomeMember2023-07-012023-09-300001075415dhc:RentalIncomeMember2022-07-012022-09-300001075415dhc:RentalIncomeMember2023-01-012023-09-300001075415dhc:RentalIncomeMember2022-01-012022-09-300001075415dhc:ResidentFeesAndServicesMember2023-07-012023-09-300001075415dhc:ResidentFeesAndServicesMember2022-07-012022-09-300001075415dhc:ResidentFeesAndServicesMember2023-01-012023-09-300001075415dhc:ResidentFeesAndServicesMember2022-01-012022-09-3000010754152023-07-012023-09-3000010754152022-07-012022-09-3000010754152022-01-012022-09-300001075415srt:AffiliatedEntityMember2023-07-012023-09-300001075415srt:AffiliatedEntityMember2022-07-012022-09-300001075415srt:AffiliatedEntityMember2023-01-012023-09-300001075415srt:AffiliatedEntityMember2022-01-012022-09-300001075415us-gaap:CommonStockMember2022-12-310001075415us-gaap:AdditionalPaidInCapitalMember2022-12-310001075415us-gaap:RetainedEarningsMember2022-12-310001075415dhc:CumulativeCommonDistributionsMember2022-12-310001075415us-gaap:RetainedEarningsMember2023-01-012023-03-3100010754152023-01-012023-03-310001075415dhc:CumulativeCommonDistributionsMember2023-01-012023-03-310001075415us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001075415us-gaap:CommonStockMember2023-01-012023-03-310001075415us-gaap:CommonStockMember2023-03-310001075415us-gaap:AdditionalPaidInCapitalMember2023-03-310001075415us-gaap:RetainedEarningsMember2023-03-310001075415dhc:CumulativeCommonDistributionsMember2023-03-3100010754152023-03-310001075415us-gaap:RetainedEarningsMember2023-04-012023-06-3000010754152023-04-012023-06-300001075415dhc:CumulativeCommonDistributionsMember2023-04-012023-06-300001075415us-gaap:CommonStockMember2023-04-012023-06-300001075415us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001075415us-gaap:CommonStockMember2023-06-300001075415us-gaap:AdditionalPaidInCapitalMember2023-06-300001075415us-gaap:RetainedEarningsMember2023-06-300001075415dhc:CumulativeCommonDistributionsMember2023-06-3000010754152023-06-300001075415us-gaap:RetainedEarningsMember2023-07-012023-09-300001075415dhc:CumulativeCommonDistributionsMember2023-07-012023-09-300001075415us-gaap:CommonStockMember2023-07-012023-09-300001075415us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001075415us-gaap:CommonStockMember2023-09-300001075415us-gaap:AdditionalPaidInCapitalMember2023-09-300001075415us-gaap:RetainedEarningsMember2023-09-300001075415dhc:CumulativeCommonDistributionsMember2023-09-300001075415us-gaap:CommonStockMember2021-12-310001075415us-gaap:AdditionalPaidInCapitalMember2021-12-310001075415us-gaap:RetainedEarningsMember2021-12-310001075415dhc:CumulativeCommonDistributionsMember2021-12-3100010754152021-12-310001075415us-gaap:RetainedEarningsMember2022-01-012022-03-3100010754152022-01-012022-03-310001075415dhc:CumulativeCommonDistributionsMember2022-01-012022-03-310001075415us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001075415us-gaap:CommonStockMember2022-01-012022-03-310001075415us-gaap:CommonStockMember2022-03-310001075415us-gaap:AdditionalPaidInCapitalMember2022-03-310001075415us-gaap:RetainedEarningsMember2022-03-310001075415dhc:CumulativeCommonDistributionsMember2022-03-3100010754152022-03-310001075415us-gaap:RetainedEarningsMember2022-04-012022-06-3000010754152022-04-012022-06-300001075415dhc:CumulativeCommonDistributionsMember2022-04-012022-06-300001075415us-gaap:CommonStockMember2022-04-012022-06-300001075415us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001075415us-gaap:CommonStockMember2022-06-300001075415us-gaap:AdditionalPaidInCapitalMember2022-06-300001075415us-gaap:RetainedEarningsMember2022-06-300001075415dhc:CumulativeCommonDistributionsMember2022-06-3000010754152022-06-300001075415us-gaap:RetainedEarningsMember2022-07-012022-09-300001075415dhc:CumulativeCommonDistributionsMember2022-07-012022-09-300001075415us-gaap:CommonStockMember2022-07-012022-09-300001075415us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001075415us-gaap:CommonStockMember2022-09-300001075415us-gaap:AdditionalPaidInCapitalMember2022-09-300001075415us-gaap:RetainedEarningsMember2022-09-300001075415dhc:CumulativeCommonDistributionsMember2022-09-3000010754152022-09-30xbrli:pure0001075415dhc:PropertiesUsedToSecureDebtMemberus-gaap:LineOfCreditMemberus-gaap:UnsecuredDebtMember2023-09-30dhc:property00010754152023-08-310001075415us-gaap:LineOfCreditMember2023-09-30dhc:state0001075415us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2023-09-300001075415dhc:SeniorLivingCommunitiesMember2023-09-300001075415dhc:JointVentureMember2023-09-30dhc:jointVenture0001075415us-gaap:CorporateJointVentureMemberdhc:SeaportInnovationLLCMember2023-09-30utr:sqft0001075415us-gaap:CorporateJointVentureMemberdhc:TheLSMDFundREITLLCMember2023-09-300001075415us-gaap:CorporateJointVentureMember2023-09-300001075415stpr:MAus-gaap:CorporateJointVentureMemberdhc:SeaportInnovationLLCMember2023-09-300001075415us-gaap:CorporateJointVentureMemberdhc:TheLSMDFundREITLLCMemberstpr:CA2023-09-300001075415dhc:SeaportInnovationLLCMember2021-12-31dhc:option0001075415us-gaap:CorporateJointVentureMemberdhc:TheLSMDFundREITLLCMemberstpr:CA2023-01-012023-09-300001075415dhc:SecuredOvernightFinancingRateSOFRMemberus-gaap:CorporateJointVentureMemberdhc:TheLSMDFundREITLLCMemberstpr:CA2023-01-012023-09-300001075415dhc:SecuredOvernightFinancingRateSOFRMemberdhc:TheLSMDFundREITLLCMemberus-gaap:CorporateJointVentureMemberus-gaap:InterestRateCapMemberstpr:CA2023-01-012023-09-300001075415us-gaap:CorporateJointVentureMemberdhc:SeaportInnovationLLCMember2021-12-012021-12-310001075415us-gaap:CorporateJointVentureMemberdhc:SeaportInnovationLLCMember2021-12-310001075415us-gaap:CorporateJointVentureMemberdhc:SeaportInnovationLLCMember2022-06-012022-06-300001075415us-gaap:CorporateJointVentureMemberdhc:SeaportInnovationLLCMember2022-06-280001075415dhc:SeniorLivingCommunitiesMemberdhc:SkilledNursingBedLicenseMember2022-06-012022-06-300001075415us-gaap:CorporateJointVentureMemberdhc:SeaportInnovationLLCMemberdhc:MedicalOfficeBuildingandLifeScienceBuildingMember2022-06-300001075415us-gaap:CorporateJointVentureMemberdhc:MedicalOfficeBuildingandLifeScienceBuildingMember2022-01-012022-01-31dhc:investor0001075415dhc:SeniorLivingCommunitiesMemberdhc:SkilledNursingBedLicenseMember2022-01-012022-01-310001075415us-gaap:CorporateJointVentureMemberdhc:DiversifiedHealthcareTrustsMemberdhc:UnrelatedInvestorOneMemberdhc:MedicalOfficeBuildingandLifeScienceBuildingMember2022-01-310001075415us-gaap:CorporateJointVentureMemberdhc:DiversifiedHealthcareTrustsMemberdhc:UnrelatedInvestorTwoMemberdhc:MedicalOfficeBuildingandLifeScienceBuildingMember2022-01-310001075415us-gaap:CorporateJointVentureMemberdhc:DiversifiedHealthcareTrustsMemberdhc:MedicalOfficeBuildingandLifeScienceBuildingMember2022-01-310001075415us-gaap:CorporateJointVentureMember2022-01-310001075415dhc:SeniorLivingCommunitiesMemberdhc:PennsylvaniaAndSouthCarolinaMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2023-09-300001075415dhc:SeniorLivingCommunitiesMemberdhc:PennsylvaniaAndSouthCarolinaMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2023-01-012023-09-300001075415dhc:SeniorLivingCommunitiesMemberdhc:PennsylvaniaAndSouthCarolinaMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2023-02-280001075415dhc:SeniorLivingCommunitiesMemberdhc:PennsylvaniaAndSouthCarolinaMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2023-02-012023-02-280001075415dhc:SkilledNursingBedLicensesMember2023-01-012023-09-300001075415us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberdhc:LifeScienceAndMedicalOfficeMember2023-09-300001075415us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberdhc:SeniorLivingCommunitiesMember2023-09-300001075415us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberdhc:LifeScienceAndMedicalOfficeMemberus-gaap:SubsequentEventMember2023-10-310001075415us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberdhc:LifeScienceAndMedicalOfficeMemberus-gaap:SubsequentEventMember2023-10-310001075415dhc:SeniorLivingCommunitiesMemberus-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMember2023-10-310001075415us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberdhc:SeniorLivingCommunitiesMemberus-gaap:SubsequentEventMember2023-10-310001075415us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberus-gaap:SubsequentEventMemberdhc:LifeScienceAndMedicalOfficeAndSeniorLivingCommunitiesMember2023-10-310001075415us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberdhc:PropertiesUnderAgreementToSellMemberus-gaap:SubsequentEventMember2023-10-270001075415dhc:LifeScienceAndMedicalOfficeAndSeniorLivingCommunitiesMember2023-01-012023-09-300001075415dhc:LifeScienceAndMedicalOfficeMember2023-09-300001075415dhc:SeniorLivingCommunitiesMember2023-01-012023-09-300001075415us-gaap:UnsecuredDebtMember2023-09-300001075415us-gaap:MortgagesMember2023-09-300001075415dhc:FinanceLeasedPropertiesMember2023-09-300001075415dhc:FinanceLeasedPropertiesMember2022-12-310001075415us-gaap:LineOfCreditMemberdhc:SecuredOvernightFinancingRateSOFRMember2023-01-012023-09-300001075415us-gaap:LineOfCreditMember2023-07-012023-09-300001075415us-gaap:LineOfCreditMember2022-07-012022-09-300001075415us-gaap:LineOfCreditMember2023-01-012023-09-300001075415us-gaap:LineOfCreditMember2022-01-012022-09-300001075415us-gaap:SeniorNotesMemberdhc:SeniorUnsecuredNotes975PercentDue2025Member2023-09-300001075415dhc:SeniorUnsecuredNotes4375PercentDue2031Memberus-gaap:SeniorNotesMember2023-09-300001075415dhc:UnsecuredDebtNotGuaranteedMember2023-09-300001075415us-gaap:LineOfCreditMember2023-01-012023-01-310001075415us-gaap:LineOfCreditMember2023-01-310001075415us-gaap:LineOfCreditMemberus-gaap:UnsecuredDebtMember2023-01-310001075415us-gaap:LineOfCreditMemberus-gaap:UnsecuredDebtMember2023-02-280001075415us-gaap:LineOfCreditMemberus-gaap:UnsecuredDebtMember2023-01-012023-09-300001075415dhc:SeniorUnsecuredNotesMemberdhc:TermLoanDue2022Member2023-01-012023-09-300001075415us-gaap:LineOfCreditMemberdhc:LondonInterbankOfferedRateMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMember2023-02-012023-02-280001075415dhc:MedicalOfficeAndLifeScienceMemberus-gaap:LineOfCreditMember2023-09-300001075415dhc:MedicalOfficeAndLifeScienceMemberus-gaap:LineOfCreditMemberus-gaap:UnsecuredDebtMember2023-06-2300010754152023-06-2200010754152023-06-230001075415dhc:MedicalOfficeMemberus-gaap:LineOfCreditMember2023-09-300001075415us-gaap:MortgagesMember2023-04-012023-04-300001075415us-gaap:MortgagesMember2023-04-300001075415us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberdhc:AlerisLifeIncMember2023-09-300001075415us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberdhc:AlerisLifeIncMember2023-09-300001075415us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberdhc:AlerisLifeIncMember2022-12-310001075415us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberdhc:AlerisLifeIncMember2022-12-310001075415us-gaap:FairValueInputsLevel3Memberdhc:SeaportInnovationLLCMemberus-gaap:FairValueMeasurementsRecurringMemberdhc:JointVentureMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001075415us-gaap:FairValueInputsLevel3Memberdhc:SeaportInnovationLLCMemberus-gaap:FairValueMeasurementsRecurringMemberdhc:JointVentureMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001075415us-gaap:FairValueInputsLevel3Memberdhc:SeaportInnovationLLCMemberus-gaap:FairValueMeasurementsRecurringMemberdhc:JointVentureMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001075415us-gaap:FairValueInputsLevel3Memberdhc:SeaportInnovationLLCMemberus-gaap:FairValueMeasurementsRecurringMemberdhc:JointVentureMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001075415dhc:TheLSMDFundREITLLCMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberdhc:JointVentureMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001075415dhc:TheLSMDFundREITLLCMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberdhc:JointVentureMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001075415dhc:TheLSMDFundREITLLCMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberdhc:JointVentureMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001075415dhc:TheLSMDFundREITLLCMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberdhc:JointVentureMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001075415us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001075415us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001075415us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001075415us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001075415us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberdhc:AlerisLifeIncMember2023-02-020001075415dhc:AlerisLifeIncMember2023-02-022023-02-020001075415us-gaap:CorporateJointVentureMemberus-gaap:MeasurementInputDiscountRateMemberdhc:SeaportInnovationLLCMember2023-09-300001075415us-gaap:CorporateJointVentureMemberdhc:SeaportInnovationLLCMemberdhc:MeasurementInputMarketCapitalizationRateMember2023-09-300001075415us-gaap:CorporateJointVentureMemberdhc:SeaportInnovationLLCMember2023-01-012023-09-300001075415us-gaap:CorporateJointVentureMemberdhc:TheLSMDFundREITLLCMembersrt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2023-09-300001075415us-gaap:CorporateJointVentureMemberdhc:TheLSMDFundREITLLCMemberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2023-09-300001075415us-gaap:CorporateJointVentureMemberdhc:TheLSMDFundREITLLCMembersrt:MinimumMemberdhc:MeasurementInputMarketCapitalizationRateMember2023-09-300001075415us-gaap:CorporateJointVentureMemberdhc:TheLSMDFundREITLLCMembersrt:MaximumMemberdhc:MeasurementInputMarketCapitalizationRateMember2023-09-300001075415us-gaap:CorporateJointVentureMemberdhc:TheLSMDFundREITLLCMember2023-01-012023-09-300001075415us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:FairValueMeasurementsNonrecurringMemberdhc:LifeSciencePropertyMember2023-07-012023-09-300001075415us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:FairValueMeasurementsNonrecurringMemberdhc:LifeSciencePropertyMember2023-09-300001075415us-gaap:FairValueMeasurementsNonrecurringMemberdhc:LifeSciencePropertyMember2023-09-300001075415us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:FairValueMeasurementsNonrecurringMemberdhc:SeniorLivingCommunityMember2023-07-012023-09-300001075415us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberus-gaap:FairValueMeasurementsNonrecurringMemberdhc:SeniorLivingCommunityMember2023-09-300001075415us-gaap:FairValueMeasurementsNonrecurringMemberdhc:SeniorLivingCommunityMember2023-09-300001075415dhc:SeniorUnsecuredNotesMemberdhc:SeniorUnsecuredNotes4.75PercentDue2024Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001075415dhc:SeniorUnsecuredNotesMemberdhc:SeniorUnsecuredNotes4.75PercentDue2024Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001075415dhc:SeniorUnsecuredNotesMemberdhc:SeniorUnsecuredNotes4.75PercentDue2024Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001075415dhc:SeniorUnsecuredNotesMemberdhc:SeniorUnsecuredNotes4.75PercentDue2024Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001075415dhc:SeniorUnsecuredNotesMemberdhc:SeniorUnsecuredNotes975PercentDue2025Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001075415dhc:SeniorUnsecuredNotesMemberdhc:SeniorUnsecuredNotes975PercentDue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001075415dhc:SeniorUnsecuredNotesMemberdhc:SeniorUnsecuredNotes975PercentDue2025Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001075415dhc:SeniorUnsecuredNotesMemberdhc:SeniorUnsecuredNotes975PercentDue2025Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001075415dhc:SeniorUnsecuredNotes4.75PercentDue2028Memberdhc:SeniorUnsecuredNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001075415dhc:SeniorUnsecuredNotes4.75PercentDue2028Memberdhc:SeniorUnsecuredNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001075415dhc:SeniorUnsecuredNotes4.75PercentDue2028Memberdhc:SeniorUnsecuredNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001075415dhc:SeniorUnsecuredNotes4.75PercentDue2028Memberdhc:SeniorUnsecuredNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001075415dhc:SeniorUnsecuredNotesMemberdhc:SeniorUnsecuredNotes4375PercentDue2031Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001075415dhc:SeniorUnsecuredNotesMemberdhc:SeniorUnsecuredNotes4375PercentDue2031Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001075415dhc:SeniorUnsecuredNotesMemberdhc:SeniorUnsecuredNotes4375PercentDue2031Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001075415dhc:SeniorUnsecuredNotesMemberdhc:SeniorUnsecuredNotes4375PercentDue2031Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001075415dhc:SeniorUnsecuredNotes5625PercentDue2042Memberdhc:SeniorUnsecuredNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001075415dhc:SeniorUnsecuredNotes5625PercentDue2042Memberdhc:SeniorUnsecuredNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001075415dhc:SeniorUnsecuredNotes5625PercentDue2042Memberdhc:SeniorUnsecuredNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001075415dhc:SeniorUnsecuredNotes5625PercentDue2042Memberdhc:SeniorUnsecuredNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001075415dhc:SeniorUnsecuredNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberdhc:SeniorUnsecuredNotes625PercentDue2046Member2023-09-300001075415dhc:SeniorUnsecuredNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberdhc:SeniorUnsecuredNotes625PercentDue2046Member2023-09-300001075415dhc:SeniorUnsecuredNotesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberdhc:SeniorUnsecuredNotes625PercentDue2046Member2022-12-310001075415dhc:SeniorUnsecuredNotesMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberdhc:SeniorUnsecuredNotes625PercentDue2046Member2022-12-310001075415us-gaap:SecuredDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001075415us-gaap:SecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001075415us-gaap:SecuredDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001075415us-gaap:SecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001075415us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-09-300001075415us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300001075415us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001075415us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001075415us-gaap:FairValueInputsLevel1Member2023-09-30dhc:security0001075415us-gaap:FairValueInputsLevel1Member2022-12-310001075415us-gaap:FairValueInputsLevel2Member2022-12-310001075415us-gaap:FairValueInputsLevel2Member2023-09-300001075415dhc:ReitManagementAndResearchMemberdhc:ShareAwardPlansMemberdhc:TrusteesMember2023-06-05dhc:trustee0001075415dhc:ReitManagementAndResearchMemberdhc:ShareAwardPlansMemberdhc:TrusteesMember2023-06-052023-06-050001075415dhc:ReitManagementAndResearchMemberdhc:ShareAwardPlansMemberdhc:OfficersAndOtherEmployeesMember2023-09-132023-09-130001075415dhc:ReitManagementAndResearchMemberdhc:ShareAwardPlansMemberdhc:OfficersAndOtherEmployeesMember2023-09-130001075415dhc:ReitManagementAndResearchMemberdhc:ShareAwardPlansMemberdhc:TrusteesMember2023-09-262023-09-260001075415dhc:ReitManagementAndResearchMemberdhc:ShareAwardPlansMember2023-09-012023-09-300001075415dhc:ReitManagementAndResearchMemberdhc:ShareAwardPlansMemberdhc:TrusteesMember2023-09-260001075415dhc:ReitManagementAndResearchMember2023-07-012023-09-300001075415dhc:ReitManagementAndResearchMember2023-01-012023-09-3000010754152023-02-162023-02-1600010754152023-05-182023-05-1800010754152023-08-172023-08-170001075415us-gaap:SubsequentEventMember2023-10-122023-10-12dhc:segment0001075415dhc:RentalIncomeMemberdhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300001075415dhc:RentalIncomeMemberdhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300001075415dhc:RentalIncomeMemberus-gaap:CorporateNonSegmentMember2023-07-012023-09-300001075415dhc:ResidentFeesAndServicesMemberdhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300001075415dhc:ResidentFeesAndServicesMemberdhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300001075415dhc:ResidentFeesAndServicesMemberus-gaap:CorporateNonSegmentMember2023-07-012023-09-300001075415dhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300001075415dhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-07-012023-09-300001075415us-gaap:CorporateNonSegmentMember2023-07-012023-09-300001075415dhc:RentalIncomeMemberdhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300001075415dhc:RentalIncomeMemberdhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300001075415dhc:RentalIncomeMemberus-gaap:CorporateNonSegmentMember2023-01-012023-09-300001075415dhc:ResidentFeesAndServicesMemberdhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300001075415dhc:ResidentFeesAndServicesMemberdhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300001075415dhc:ResidentFeesAndServicesMemberus-gaap:CorporateNonSegmentMember2023-01-012023-09-300001075415dhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300001075415dhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-01-012023-09-300001075415us-gaap:CorporateNonSegmentMember2023-01-012023-09-300001075415dhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001075415dhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-09-300001075415dhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2023-09-300001075415us-gaap:CorporateNonSegmentMember2023-09-300001075415dhc:RentalIncomeMemberdhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001075415dhc:RentalIncomeMemberdhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001075415dhc:RentalIncomeMemberus-gaap:CorporateNonSegmentMember2022-07-012022-09-300001075415dhc:ResidentFeesAndServicesMemberdhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001075415dhc:ResidentFeesAndServicesMemberdhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001075415dhc:ResidentFeesAndServicesMemberus-gaap:CorporateNonSegmentMember2022-07-012022-09-300001075415dhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001075415dhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300001075415us-gaap:CorporateNonSegmentMember2022-07-012022-09-300001075415dhc:RentalIncomeMemberdhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001075415dhc:RentalIncomeMemberdhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001075415dhc:RentalIncomeMemberus-gaap:CorporateNonSegmentMember2022-01-012022-09-300001075415dhc:ResidentFeesAndServicesMemberdhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001075415dhc:ResidentFeesAndServicesMemberdhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001075415dhc:ResidentFeesAndServicesMemberus-gaap:CorporateNonSegmentMember2022-01-012022-09-300001075415dhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300001075415us-gaap:CorporateNonSegmentMember2022-01-012022-09-300001075415dhc:OfficePortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-12-310001075415dhc:SeniorHousingOperatingPortfolioSegmentMemberus-gaap:OperatingSegmentsMember2022-12-310001075415us-gaap:CorporateNonSegmentMember2022-12-310001075415us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberdhc:FiveStarQualityCareIncMemberdhc:SeniorLivingCommunityMember2021-12-31dhc:community0001075415dhc:FiveStarQualityCareIncMemberdhc:SeniorLivingCommunityMemberus-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember2021-12-31dhc:unit0001075415dhc:FiveStarQualityCareIncMemberdhc:SeniorLivingCommunityMemberus-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember2022-07-012022-09-300001075415dhc:FiveStarQualityCareIncMemberdhc:SeniorLivingCommunityMemberus-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember2022-01-012022-09-300001075415dhc:FiveStarQualityCareIncMemberdhc:SeniorLivingCommunityMembersrt:AffiliatedEntityMember2023-01-012023-09-300001075415dhc:FiveStarQualityCareIncMemberdhc:SeniorLivingCommunityMembersrt:AffiliatedEntityMember2022-01-012022-09-300001075415dhc:FiveStarQualityCareIncMember2023-07-012023-09-300001075415dhc:FiveStarQualityCareIncMember2022-07-012022-09-300001075415dhc:FiveStarQualityCareIncMember2023-01-012023-09-300001075415dhc:FiveStarQualityCareIncMember2022-01-012022-09-300001075415us-gaap:OperatingExpenseMemberdhc:FiveStarQualityCareIncMember2023-07-012023-09-300001075415us-gaap:OperatingExpenseMemberdhc:FiveStarQualityCareIncMember2022-07-012022-09-300001075415us-gaap:OperatingExpenseMemberdhc:FiveStarQualityCareIncMember2023-01-012023-09-300001075415us-gaap:OperatingExpenseMemberdhc:FiveStarQualityCareIncMember2022-01-012022-09-300001075415dhc:RehabilitationServicesMemberdhc:FiveStarQualityCareIncMember2023-07-012023-09-300001075415dhc:RehabilitationServicesMemberdhc:FiveStarQualityCareIncMember2022-07-012022-09-300001075415dhc:RehabilitationServicesMemberdhc:FiveStarQualityCareIncMember2023-01-012023-09-300001075415dhc:RehabilitationServicesMemberdhc:FiveStarQualityCareIncMember2022-01-012022-09-300001075415dhc:ThirdPartyManagersMemberdhc:SeniorLivingCommunityMembersrt:AffiliatedEntityMember2023-01-012023-09-300001075415dhc:ThirdPartyManagersMemberdhc:SeniorLivingCommunityMembersrt:AffiliatedEntityMember2022-01-012022-09-300001075415dhc:ThirdPartyManagersMemberdhc:SeniorLivingCommunityMembersrt:AffiliatedEntityMember2023-07-012023-09-300001075415dhc:ThirdPartyManagersMemberdhc:SeniorLivingCommunityMembersrt:AffiliatedEntityMember2022-07-012022-09-300001075415dhc:BasicHousingAndSupportServicesMemberdhc:ResidentFeesAndServicesMember2023-07-012023-09-300001075415dhc:BasicHousingAndSupportServicesMemberdhc:ResidentFeesAndServicesMember2022-07-012022-09-300001075415dhc:BasicHousingAndSupportServicesMemberdhc:ResidentFeesAndServicesMember2023-01-012023-09-300001075415dhc:BasicHousingAndSupportServicesMemberdhc:ResidentFeesAndServicesMember2022-01-012022-09-300001075415dhc:ResidentFeesAndServicesMemberdhc:MedicareAndMedicaidProgramsMember2023-07-012023-09-300001075415dhc:ResidentFeesAndServicesMemberdhc:MedicareAndMedicaidProgramsMember2022-07-012022-09-300001075415dhc:ResidentFeesAndServicesMemberdhc:MedicareAndMedicaidProgramsMember2023-01-012023-09-300001075415dhc:ResidentFeesAndServicesMemberdhc:MedicareAndMedicaidProgramsMember2022-01-012022-09-300001075415dhc:PrivatePayAndOtherThirdPartyPayerServicesMemberdhc:ResidentFeesAndServicesMember2023-07-012023-09-300001075415dhc:PrivatePayAndOtherThirdPartyPayerServicesMemberdhc:ResidentFeesAndServicesMember2022-07-012022-09-300001075415dhc:PrivatePayAndOtherThirdPartyPayerServicesMemberdhc:ResidentFeesAndServicesMember2023-01-012023-09-300001075415dhc:PrivatePayAndOtherThirdPartyPayerServicesMemberdhc:ResidentFeesAndServicesMember2022-01-012022-09-30dhc:employee0001075415dhc:ReitManagementAndResearchMemberdhc:SeniorLivingCommunityMember2023-01-012023-09-30dhc:agreement0001075415dhc:ReitManagementAndResearchMember2022-07-012022-09-300001075415dhc:ReitManagementAndResearchMember2022-01-012022-09-30dhc:jointVenture_arrangement0001075415us-gaap:RelatedPartyMemberdhc:AlerisLifeIncMember2023-03-200001075415dhc:AlerisLifeIncMemberdhc:AlerisLifeIncMember2023-03-200001075415dhc:AlerisLifeIncMember2023-02-020001075415us-gaap:RelatedPartyMemberdhc:ReitManagementAndResearchLLCMember2023-01-012023-09-300001075415us-gaap:RelatedPartyMemberdhc:ReitManagementAndResearchLLCMember2023-09-300001075415dhc:RentalIncomeMemberdhc:ReitManagementAndResearchLLCMember2023-07-012023-09-300001075415dhc:RentalIncomeMemberdhc:ReitManagementAndResearchLLCMember2022-07-012022-09-300001075415dhc:RentalIncomeMemberdhc:ReitManagementAndResearchLLCMember2023-01-012023-09-300001075415dhc:RentalIncomeMemberdhc:ReitManagementAndResearchLLCMember2022-01-012022-09-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC  20549 
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
For the quarterly period ended September 30, 2023
OR 
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
Commission File Number 1-15319 
DIVERSIFIED HEALTHCARE TRUST
(Exact Name of Registrant as Specified in Its Charter) 
Maryland 04-3445278
(State or Other Jurisdiction of Incorporation or
Organization)		 (IRS Employer Identification No.)
 Two Newton Place, 255 Washington Street, Suite 300, Newton, MA 02458-1634
(Address of Principal Executive Offices) (Zip Code) 
617 - 796 - 8350
(Registrant's Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:
Title Of Each ClassTrading Symbol(s)Name Of Each Exchange On Which Registered
Common Shares of Beneficial InterestDHCThe Nasdaq Stock Market LLC
5.625% Senior Notes due 2042DHCNIThe Nasdaq Stock Market LLC
6.25% Senior Notes due 2046DHCNLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant:  (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒  No ☐ 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒  No ☐ 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. 
Large accelerated filer☐ Accelerated filer☒
Non-accelerated filer☐ Smaller reporting company☐
Emerging growth company☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒
Number of registrant's common shares outstanding as of October 27, 2023: 240,450,349

DIVERSIFIED HEALTHCARE TRUST
FORM 10-Q
 
September 30, 2023
 
INDEX
  Page
 
   
   
 
   
 
   
 
   
 
   
   
   
   
 
   
 
   
   
   
 
 
References in this Quarterly Report on Form 10-Q to the Company, we, us or our include Diversified Healthcare Trust and its consolidated subsidiaries unless otherwise expressly stated or the context indicates otherwise.


PART I.  Financial Information
 
Item 1.  Financial Statements.
 
DIVERSIFIED HEALTHCARE TRUST
CONDENSED CONSOLIDATED BALANCE SHEETS
(dollars in thousands, except share data)
(unaudited)
 September 30,December 31,
 20232022
Assets  
Real estate properties:  
Land$652,707 $668,918 
Buildings and improvements6,114,398 6,023,625 
Total real estate properties, gross6,767,105 6,692,543 
Accumulated depreciation(1,965,948)(1,828,352)
Total real estate properties, net4,801,157 4,864,191 
Investments in unconsolidated joint ventures153,744 155,477 
Assets of properties held for sale24,643 385 
Cash and cash equivalents278,122 658,065 
Restricted cash983 30,237 
Acquired real estate leases and other intangible assets, net36,605 45,351 
Other assets, net235,002 248,387 
Total assets$5,530,256 $6,002,093 
Liabilities and Shareholders' Equity  
Secured credit facility$450,000 $700,000 
Senior unsecured notes, net2,321,320 2,317,700 
Secured debt and finance leases, net13,660 30,177 
Liabilities of properties held for sale427 — 
Accrued interest32,045 29,417 
Other liabilities271,278 286,188 
Total liabilities3,088,730 3,363,482 
Commitments and contingencies
Shareholders' equity:  
Common shares of beneficial interest, $.01 par value: 300,000,000 shares authorized, 240,457,549 and 239,694,842 shares issued and outstanding, respectively
2,405 2,397 
Additional paid in capital4,618,138 4,617,031 
Cumulative net income1,880,842 2,071,850 
Cumulative distributions(4,059,859)(4,052,667)
Total shareholders' equity2,441,526 2,638,611 
Total liabilities and shareholders' equity$5,530,256 $6,002,093 
 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
1
DIVERSIFIED HEALTHCARE TRUST
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(amounts in thousands, except per share data)
(unaudited)
 Three Months Ended September 30,Nine Months Ended September 30,
 2023202220232022
Revenues:    
Rental income$63,390 $63,960 $191,201 $191,767 
Residents fees and services293,134 258,960 857,572 754,914 
Total revenues356,524 322,920 1,048,773 946,681 
Expenses:    
Property operating expenses298,432 289,096 870,740 823,904 
Depreciation and amortization67,236 60,407 200,430 175,927 
General and administrative6,954 6,179 20,111 20,671 
Acquisition and certain other transaction related costs3,676 289 9,812 1,826 
Impairment of assets1,156 — 18,380 — 
Total expenses377,454 355,971 1,119,473 1,022,328 
(Loss) gain on sale of properties— (5,044)1,233 322,064 
Gains and losses on equity securities, net— (2,674)8,126 (21,384)
Interest and other income3,243 4,099 12,572 6,760 
Interest expense (including net amortization of debt premiums, discounts and issuance costs of $2,293, $1,908, $6,616 and $6,698, respectively)
(47,758)(46,936)(142,922)(160,042)
Loss on modification or early extinguishment of debt— — (1,075)(30,043)
(Loss) income before income tax expense and equity in net (losses) earnings of investees(65,445)(83,606)(192,766)41,708 
Income tax expense(189)(13)(379)(845)
Equity in net (losses) earnings of investees(145)2,127 2,137 8,685 
Net (loss) income$(65,779)$(81,492)$(191,008)$49,548 
Weighted average common shares outstanding (basic and diluted)238,892 238,344 238,722 238,231 
Per common share amounts (basic and diluted):    
Net (loss) income$(0.28)$(0.34)$(0.80)$0.21 
 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
2
DIVERSIFIED HEALTHCARE TRUST
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(dollars in thousands)
(unaudited)
Number of
Shares		Common
Shares		Additional
Paid In
Capital		Cumulative
Net Income		Cumulative DistributionsTotal Equity
Balance at December 31, 2022:239,694,842 $2,397 $4,617,031 $2,071,850 $(4,052,667)$2,638,611 
Net loss— — — (52,658)— (52,658)
Distributions— — — — (2,397)(2,397)
Share grants— — 270 — — 270 
Share repurchases(5,975)— (6)— — (6)
Share forfeitures(6,400)— (1)— — (1)
Balance at March 31, 2023:239,682,467 2,397 4,617,294 2,019,192 (4,055,064)2,583,819 
Net loss— — — (72,571)— (72,571)
Distributions— — — — (2,397)(2,397)
Share grants140,000 1 567 — — 568 
Share repurchases(24,513)— (27)— — (27)
Share forfeitures(5,600)— (3)— — (3)
Balance at June 30, 2023:239,792,354 2,398 4,617,831 1,946,621 (4,057,461)2,509,389 
Net loss— — — (65,779)— (65,779)
Distributions— — — — (2,398)(2,398)
Share grants820,000 8 662 — — 670 
Share repurchases(151,405)(1)(352)— — (353)
Share forfeitures(3,400)— (3)— — (3)
Balance at September 30, 2023:240,457,549 $2,405 $4,618,138 $1,880,842 $(4,059,859)$2,441,526 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
DIVERSIFIED HEALTHCARE TRUST
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (CONTINUED)
(dollars in thousands)
(unaudited)
Number of
Shares		Common
Shares		Additional
Paid In
Capital		Cumulative
Net Income		Cumulative DistributionsTotal Equity
Balance at December 31, 2021:238,994,894 $2,390 $4,615,475 $2,087,624 $(4,043,099)$2,662,390 
Net income— — — 240,423 — 240,423 
Distributions— — — — (2,390)(2,390)
Share grants— — 318 — — 318 
Share repurchases(1,698)— (5)— — (5)
Share forfeitures(4,900)— (3)— — (3)
Balance at March 31, 2022:238,988,296 2,390 4,615,785 2,328,047 (4,045,489)2,900,733 
Net loss— — — (109,383)— (109,383)
Distributions— — — — (2,390)(2,390)
Share grants140,000 1 668 — — 669 
Share forfeitures(4,800)— (4)— — (4)
Balance at June 30, 2022:239,123,496 2,391 4,616,449 2,218,664 (4,047,879)2,789,625 
Net loss— — — (81,492)— (81,492)
Distributions— — — — (2,391)(2,391)
Share grants707,000 7 470 — — 477 
Share repurchases(122,403)(1)(159)— — (160)
Share forfeitures(3,600)— (4)— — (4)
Balance at September 30, 2022:239,704,493 $2,397 $4,616,756 $2,137,172 $(4,050,270)$2,706,055 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4
DIVERSIFIED HEALTHCARE TRUST
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(dollars in thousands)
(unaudited)
 Nine Months Ended September 30,
 20232022
Cash flows from operating activities:  
Net (loss) income $(191,008)$49,548 
Adjustments to reconcile net (loss) income to cash provided by (used in) operating activities:  
Depreciation and amortization200,430 175,927 
Net amortization of debt premiums, discounts and issuance costs6,616 6,698 
Straight line rental income1,333 (7,193)
Amortization of acquired real estate leases(264)204 
Loss on modification or early extinguishment of debt1,075 30,043 
Impairment of assets18,380 — 
Gain on sale of properties(1,233)(322,064)
Gains and losses on equity securities, net(8,126)21,384 
Other non-cash adjustments, net(1,328)(1,376)
Unconsolidated joint venture distributions3,870 7,400 
Equity in net earnings of investees(2,137)(8,685)
Change in assets and liabilities:  
Deferred leasing costs, net(7,995)(6,188)
Other assets4,315 9,809 
Accrued interest2,628 2,312 
Other liabilities(8,864)5,233 
Net cash provided by (used in) operating activities17,692 (36,948)
Cash flows from investing activities:  
Real estate acquisitions— (75,105)
Real estate improvements(168,400)(189,118)
Proceeds from sale of properties, net3,548 822 
Proceeds from sale of properties to joint venture, net— 638,488 
Proceeds from sale of interest in joint venture, net— 108,626 
Proceeds from AlerisLife Inc. tender offer14,006 — 
Net cash (used in) provided by investing activities(150,846)483,713 
Cash flows from financing activities:  
Repayments of borrowings on credit facility(250,000)(100,000)
Redemption of senior unsecured notes— (500,000)
Repayment of other debt(16,408)(28,373)
Loss on early extinguishment of debt settled in cash— (24,375)
Payment of debt issuance costs(2,057)(2,821)
Repurchase of common shares(386)(165)
Distributions to shareholders(7,192)(7,171)
Net cash used in financing activities(276,043)(662,905)
Decrease in cash and cash equivalents and restricted cash(409,197)(216,140)
Cash and cash equivalents and restricted cash at beginning of period688,302 1,016,945 
Cash and cash equivalents and restricted cash at end of period$279,105 $800,805 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5
DIVERSIFIED HEALTHCARE TRUST
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(dollars in thousands)
(unaudited)
Nine Months Ended September 30,
20232022
Supplemental cash flow information:  
Interest paid$133,695 $151,032 
Income taxes paid$677 $905 
Non-cash investing activities:
Decrease in real estate, net resulting from the deconsolidation of investments that were previously consolidated$— $(355,669)
Real estate improvements accrued, not paid$29,560 $24,218 
Capitalized interest$17 $— 
Supplemental disclosure of cash and cash equivalents and restricted cash:
The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within our condensed consolidated balance sheets to the amount shown in our condensed consolidated statements of cash flows:
As of September 30,
20232022
Cash and cash equivalents$278,122 $691,040 
Restricted cash (1)
983 109,765 
Total cash and cash equivalents and restricted cash shown in our condensed consolidated statements of cash flows$279,105 $800,805 
(1) As of September 30, 2022, restricted cash consisted of proceeds from the sale of assets and proceeds from the sale of joint venture interests held as collateral pursuant to the agreement governing our credit facility, or our credit agreement. Subsequently, these funds were used to pay for approved expenditures in accordance with our credit agreement. Restricted cash also consists of amounts escrowed for real estate taxes, insurance and capital expenditures at certain of our mortgaged properties.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


6
DIVERSIFIED HEALTHCARE TRUST
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(dollar amounts in thousands, except per share data or as otherwise stated)
 
Note 1.  Basis of Presentation
The accompanying condensed consolidated financial statements of Diversified Healthcare Trust and its subsidiaries, or we, us, or our, are unaudited. Certain information and disclosures required by U.S. generally accepted accounting principles, or GAAP, for complete financial statements have been condensed or omitted. We believe the disclosures made are adequate to make the information presented not misleading. However, the accompanying condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes contained in our Annual Report on Form 10-K for the year ended December 31, 2022, or our Annual Report.
In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair statement of results for the interim period have been included. All intercompany transactions and balances with or among our consolidated subsidiaries have been eliminated. Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year.
The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect reported amounts. Actual results could differ from those estimates. Significant estimates in our condensed consolidated financial statements include purchase price allocations, useful lives of fixed assets and impairments of real estate and intangible assets.
We have been, are currently, and expect in the future to be involved in claims, lawsuits, and regulatory and other governmental audits, investigations and proceedings arising in the ordinary course of our business, some of which may involve material amounts. Also, the defense and resolution of these claims, lawsuits, and regulatory and other governmental audits, investigations and proceedings may require us to incur significant expense. We account for claims and litigation losses in accordance with the Financial Accounting Standards Board Accounting Standards Codification Topic 450, Contingencies, or ASC 450. Under ASC 450, loss contingency provisions are recorded for probable and estimable losses at our best estimate of a loss or, when a best estimate cannot be made, at our estimate of the minimum loss. These estimates are often developed prior to knowing the amount of the ultimate loss, require the application of considerable judgment, and are refined as additional information becomes known. Accordingly, we are often initially unable to develop a best estimate of loss and therefore the estimated minimum loss amount, which could be zero, is recorded; and then, as information becomes known, the minimum loss amount is updated, as appropriate. A minimum or best estimate amount may be increased or decreased when events result in a changed expectation.
Going Concern
The senior living industry has been adversely affected by a slow recovery from the COVID-19 pandemic, as well as economic and market conditions. These conditions continue to have a significant negative impact on our results of operations, financial position and cash flows. Although there have been signs of recovery and increased demand when compared to the low levels during the COVID-19 pandemic, the recovery of our senior housing operating portfolio, or SHOP, segment has been slower than previously anticipated and uneven, and we cannot be sure when or if the senior living business will return to historic pre-pandemic levels. To mitigate the effects of the slow recovery coming from the COVID-19 pandemic and the increased variability in operating cash flows from our SHOP communities, we continue to work with our senior living operators to manage costs, especially labor costs, and to increase rates and occupancy. However, increased operating costs resulting from difficult labor market conditions, wage and commodity price inflation and increased insurance costs, among other things, continue to negatively impact margins. Additionally, while our senior living operators have increased rates, those rates are increasing gradually and are not increasing at the same pace as our costs, putting further pressure on our margins. In order to increase the probability of a recovery of our cash flows, we have continued to invest capital in our SHOP segment, which has reduced our cash balances since the filing of our Annual Report on March 1, 2023. As a result of our decreased cash balances, we have deferred, and may continue to defer, future capital expenditures to preserve liquidity, which may slow the pace of any recovery of our cash flows. As of September 30, 2023, our ratio of consolidated income available for debt service to debt service was below the 1.5x incurrence requirement under our credit agreement and our public debt covenants, and we cannot be certain how long this ratio will remain below 1.5x. We are unable to refinance existing or maturing debt or issue new debt until this ratio is at or above 1.5x on a pro forma basis. As of September 30, 2023, we had $278,122 of cash and cash equivalents and $700,000 of outstanding debt due within one year from the date of issuance of these financial statements, including $450,000 in outstanding borrowings under our credit facility, which matures on January 15, 2024, and $250,000 of senior notes that mature
7
DIVERSIFIED HEALTHCARE TRUST
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(dollar amounts in thousands, except per share data or as otherwise stated)
on May 1, 2024. Our credit facility is secured by 62 properties which had an appraised value of approximately $1,114,270 based on appraisals completed in 2023.
Based on the challenges described above, as well as our reduced cash balances, additional capital commitments in both our Office Portfolio and SHOP segments and upcoming debt maturities, we have concluded that there is substantial doubt about our ability to continue as a going concern for at least one year from the date of issuance of these financial statements. In September 2023, subsequent to the termination of our proposed merger with Office Properties Income Trust, or OPI, we engaged B. Riley Securities, Inc., or B. Riley, as a financial advisor to help us evaluate our options to address our near term capital needs, including the upcoming debt maturities described above. Among the alternatives being considered to address our near term capital needs are raising permissible new capital, including by selling assets, as well as seeking an extension of the maturity date of our credit facility. Regarding any new capital that may be raised, we are limited in the type of financings we can pursue as we cannot currently refinance existing or maturing debt or issue new debt, as described above. We are also engaging in discussions with the lenders under our $450,000 credit facility regarding an amendment to our credit agreement to extend the maturity date of the facility, amend certain covenants and allow us to repay maturing debt, among other things. While we believe that the new capital we expect to raise, including proceeds from our planned asset sales, and the possible extension of the maturity date of our credit facility, will alleviate the substantial doubt about our ability to continue as a going concern, we cannot provide assurance that we will raise new capital or sell assets or that any new capital raised, including proceeds from our planned asset sales, will be sufficient to repay our maturing debt or that our lenders will agree to an extension of the maturity date of our credit facility. Due to challenging capital market conditions, in particular with respect to commercial real estate, we do not believe that it is probable, as of the date of issuance of these financial statements, that we will raise sufficient new capital, including proceeds from our planned asset sales, to meet our upcoming contractual commitments. As of November 1, 2023, we cannot demonstrate that our management's plans to alleviate the substantial doubt about our ability to continue as a going concern will be probable in mitigating the conditions that raise the substantial doubt because our plan to raise permissible new capital, including proceeds from our planned asset sales, and to extend the maturity date of our credit facility, is subject to market conditions and lender approvals, among other things, which are beyond our control.
Our condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.
Termination of Merger Agreement with Office Properties Income Trust
On April 11, 2023, we and OPI entered into an Agreement and Plan of Merger, or the Merger Agreement, pursuant to which we and OPI agreed that we would merge with and into OPI, with OPI as the surviving entity in the merger, subject to the terms and conditions of the Merger Agreement. On September 1, 2023, we and OPI mutually agreed to terminate the Merger Agreement and entered into a termination agreement, or the Termination Agreement. The mutual termination of the Merger Agreement was separately recommended by special committees of our and OPI’s respective board of trustees and approved by our and OPI’s respective board of trustees.
Pursuant to the Termination Agreement, the termination of the Merger Agreement was effective as of September 1, 2023. Neither we nor OPI are required to pay any termination fee as a result of the mutual decision to terminate the Merger Agreement. We and OPI will bear our and its respective costs and expenses related to the Merger Agreement and the transactions contemplated thereby in accordance with the terms of the Merger Agreement.
8
DIVERSIFIED HEALTHCARE TRUST
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(dollar amounts in thousands, except per share data or as otherwise stated)
Note 2.  Real Estate Investments
As of September 30, 2023, we wholly owned 376 properties located in 36 states and Washington, D.C., including six properties classified as held for sale and five closed senior living communities, and we owned an equity interest in each of two unconsolidated joint ventures that own medical office and life science properties located in five states.
Joint Venture Activities:
As of September 30, 2023, we had equity investments in joint ventures as follows:
Joint VentureDHC Ownership
DHC Carrying Value of Investment at September 30, 2023
Number of PropertiesLocationSquare Feet
Seaport Innovation LLC10%$107,773 1MA1,134,479 
The LSMD Fund REIT LLC20%45,971 10CA, MA, NY, TX, WA1,068,763 
$153,744 112,203,242 
The following table provides a summary of the mortgage debts of these joint ventures:
Joint VentureCoupon RateMaturity Date
Principal Balance at September 30, 2023 (1)
Mortgage Notes Payable (secured by one property in Massachusetts) (2)
3.53%8/6/2026$620,000 
Mortgage Notes Payable (secured by nine properties in five states) (3)
3.46%2/11/2032189,800 
Mortgage Notes Payable (secured by one property in California) (3) (4)
5.90%2/9/2024266,825 
4.10%$1,076,625 
(1)Amounts are not adjusted for our minority equity interest.
(2)Following the deconsolidation in December 2021 of the net assets of an unconsolidated joint venture that owns a life science property located in Boston, Massachusetts, or the Seaport JV, we no longer include this $620,000 of secured debt financing in our condensed consolidated balance sheet; however, we continue to provide certain guaranties on this debt.
(3)The debt securing these properties is non-recourse to us.
(4)The maturity date of February 9, 2024 is subject to three, one year extension options and requires interest to be paid at an annual rate based on the secured overnight financing rate, or SOFR, plus a premium of 1.90%. The interest rate is as of September 30, 2023. This joint venture has also purchased an interest rate cap through February 2024 with a SOFR strike rate equal to 4.00%.

In December 2021, we sold an additional 35% equity interest from our then remaining 55% equity interest in the Seaport JV to another third party institutional investor for $378,000, before closing costs and other adjustments. Effective as of the date of the sale, we deconsolidated this joint venture and we now account for this joint venture using the equity method of accounting under the fair value option. In June 2022, we sold an additional 10% equity interest from our then remaining 20% equity interest in the Seaport JV to an existing joint venture investor for $108,000, before closing costs and other adjustments. We recognized a net loss on sale of $1,226 related to this transaction during the nine months ended September 30, 2022, which is included in (loss) gain on sale of properties in our condensed consolidated statements of comprehensive income (loss). After giving effect to these sales, we continue to own a 10% equity interest in this joint venture. Our initial investment amount was based on a property valuation of $1,700,000, less $620,000 of existing mortgage debts on the property that this joint venture assumed. See Note 5 for more information regarding the valuation of our investment in this joint venture.
In January 2022, we entered into a joint venture with two unrelated third party institutional investors for 10 medical office and life science properties we owned, or the LSMD JV. We sold equity interests in this joint venture to those investors for aggregate proceeds, before closing costs and other adjustments, of approximately $653,300. We deconsolidated the net assets of these properties effective as of the date of the sale and recognized a net gain on sale of $322,468 related to this transaction during the nine months ended September 30, 2022, which is included in (loss) gain on sale of properties in our condensed consolidated statements of comprehensive income (loss). The equity interests that the investors acquired from us equaled 41% and 39%, respectively, of the total equity interests in the joint venture and we retained a 20% equity interest in the joint venture. Following the sale, we account for this joint venture using the equity method of accounting under the fair value option. The initial investment amounts were based upon a property valuation of approximately $702,500, less approximately $456,600 of secured debt on the properties incurred by this joint venture. See Note 5 for more information regarding the valuation of our investment in this joint venture.
9
DIVERSIFIED HEALTHCARE TRUST
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(dollar amounts in thousands, except per share data or as otherwise stated)
Acquisitions and Dispositions:
We did not acquire any properties during the nine months ended September 30, 2023.
During the nine months ended September 30, 2023, we sold three properties for an aggregate sales price of $2,800, excluding closing costs, as presented in the table below. The sales of these properties do not represent significant dispositions, individually or in the aggregate, and we do not believe these sales represent a strategic shift in our business. As a result, the results of operations for these properties are included in continuing operations through the date of sale of such properties in our condensed consolidated statements of comprehensive income (loss).
Date of SaleLocationType of PropertyNumber of Properties
Sales Price (1)
Gain on Sale
February 2023Pennsylvania and South CarolinaSenior Living3$2,800 $293 
(1)Sales price excludes closing costs.
During the nine months ended September 30, 2023, we recognized a gain of $940 related to the sales of skilled nursing bed licenses at certain of our senior living communities.
As of September 30, 2023, we had six properties classified as held for sale in our condensed consolidated balance sheet as follows:
Type of PropertyNumber of PropertiesReal Estate Properties, Net
Life Science and Medical Office4$21,372 
Senior Living22,740 
6$24,112 
In October 2023, two of the four life science and medical office properties, and one of the two senior living communities, which were classified as held for sale in the table above, were sold for an aggregate sales price of $10,830, excluding closing costs.
As of October 27, 2023, we had one property under an agreement to sell for a sales price of approximately $1,800, excluding closing costs. We may not complete the sales of any or all of the properties we currently plan to sell. Also, we may sell some or all of these properties at amounts that are less than currently expected and/or less than the carrying values of such properties and we may incur losses on any such sales as a result.
Impairment:
We regularly evaluate our assets for indicators of impairment. Impairment indicators may include declining tenant or resident occupancy, weak or declining profitability from the property, decreasing tenant cash flows or liquidity, our decision to dispose of an asset before the end of its estimated useful life, and legislative, market or industry changes that could permanently reduce the value of an asset. If indicators of impairment are present, we evaluate the carrying value of the affected assets by comparing it to the expected future undiscounted cash flows to be generated from those assets. The future cash flows are subjective and are based in part on assumptions regarding hold periods, market rents and terminal capitalization rates. If the sum of these expected future cash flows is less than the carrying value, we reduce the net carrying value of the asset to its estimated fair value.
During the nine months ended September 30, 2023, we recorded impairment charges of $14,763 related to four life science and medical office properties and one senior living community that were classified as held for sale as of September 30, 2023. We also recorded impairment charges of $3,617 to adjust the carrying value of one senior living community to its estimated fair value.
10
DIVERSIFIED HEALTHCARE TRUST
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(dollar amounts in thousands, except per share data or as otherwise stated)
Note 3.  Leases
We are a lessor of medical office and life science properties, senior living communities and other healthcare related properties. Our leases provide our tenants with the contractual right to use and economically benefit from all of the premises demised under the leases; therefore, we have determined to evaluate our leases as lease arrangements.
Our leases provide for base rent payments and, in addition, may include variable payments. Rental income from operating leases, including any payments derived by index or market based indices, is recognized on a straight line basis over the lease term when we have determined that the collectability of substantially all of the lease payments is probable. Some of our leases have options to extend or terminate the lease exercisable at the option of our tenants, which are considered when determining the lease term.
We increased rental income to record revenue on a straight line basis by $676 and $2,738 for the three months ended September 30, 2023 and 2022, respectively, and $7,193 for the nine months ended September 30, 2022. We decreased rental income to record revenue on a straight line basis by $1,333 for the nine months ended September 30, 2023. Rents receivable, excluding receivables related to our properties classified as held for sale, if any, include $74,884 and $76,363 of straight line rent receivables at September 30, 2023 and December 31, 2022, respectively, and are included in other assets, net in our condensed consolidated balance sheets.
We do not include in our measurement of our lease receivables certain variable payments, including changes in the index or market based indices after the inception of the lease, certain tenant reimbursements and other income until the specific events that trigger the variable payments have occurred. Such payments totaled $12,018 and $11,312 for the three months ended September 30, 2023 and 2022, respectively, of which tenant reimbursements totaled $11,965 and $11,263, respectively, and $36,579 and $32,450 for the nine months ended September 30, 2023 and 2022, respectively, of which tenant reimbursements totaled $36,414 and $32,276, respectively.
Right of Use Asset and Lease Liability: For leases where we are the lessee, we recognized a right of use asset and a lease liability equal to the present value of the minimum lease payments with rental payments being applied to the lease liability and the right of use asset being amortized over the term of the lease. The values of the right of use assets and related liabilities representing our future obligation under the respective lease arrangements for which we are the lessee were $24,163 and $24,545, respectively, as of September 30, 2023, and $26,508 and $26,889, respectively, as of December 31, 2022. The right of use assets and related lease liabilities are included within other assets, net and other liabilities, respectively, within our condensed consolidated balance sheets. In addition, we lease equipment at certain of our managed senior living communities. These leases are short term in nature, are cancelable with no fee or do not result in an annual expense in excess of our capitalization policy and, as a result, are not recorded on our condensed consolidated balance sheets.
Note 4.  Indebtedness
Our principal debt obligations, excluding any debt obligations of our joint ventures, at September 30, 2023 were: (1) $450,000 of outstanding borrowings under our credit facility; (2) $2,350,000 outstanding principal amount of senior unsecured notes; and (3) $9,504 principal amount of a mortgage note secured by one property. This mortgaged property had a net book value of $12,962 at September 30, 2023. We also had two properties subject to finance leases that expire in 2026 with lease obligations totaling $4,156 at September 30, 2023; these two properties had a net book value of $23,140 and $22,347 at September 30, 2023 and December 31, 2022, respectively.
We have a $450,000 credit facility that is used for general business purposes and matures in January 2024. We are required to pay interest on the amount outstanding under our credit facility at a rate of SOFR plus a premium, which was 290 basis points per annum at September 30, 2023. As of September 30, 2023, our credit facility required interest to be paid on borrowings at the annual rate of 8.3%, plus a facility fee of $338 per quarter. The weighted average annual interest rates for borrowings under our credit facility were 8.3% and 4.8% for the three months ended September 30, 2023 and 2022, respectively, and 7.8% and 3.8% for the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023 and October 27, 2023, we were fully drawn under our credit facility. We are also engaging in discussions with the lenders under our $450,000 credit facility regarding an amendment to our credit agreement to extend the maturity date of the facility, amend certain covenants and allow us to repay maturing debt, among other things.
11
DIVERSIFIED HEALTHCARE TRUST
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(dollar amounts in thousands, except per share data or as otherwise stated)
As of September 30, 2023, all $500,000 of our 9.75% senior notes due 2025 and all $500,000 of our 4.375% senior notes due 2031 were fully and unconditionally guaranteed, on a joint and several basis and on a senior unsecured basis, by all of our subsidiaries, except for certain excluded subsidiaries, including pledged subsidiaries under our credit agreement. The notes and the guarantees are effectively subordinated to all of our and the subsidiary guarantors' secured indebtedness, respectively, to the extent of the value of the collateral securing such secured indebtedness, and are structurally subordinated to all indebtedness and other liabilities and any preferred equity of any of our subsidiaries that do not guarantee the notes. Our remaining $1,350,000 of senior unsecured notes do not have the benefit of any guarantees as of September 30, 2023.
In January 2023, pursuant to our credit agreement, we repaid $113,627 in outstanding borrowings under our credit facility and the facility commitments were reduced to $586,373.
In February 2023, we and our lenders further amended our credit agreement. Pursuant to the amendment:
•the waiver of the fixed charge coverage ratio covenant has been extended through the maturity date of our credit facility, or January 15, 2024;
•the minimum liquidity requirement was decreased from $200,000 to $100,000;
•the facility commitments were reduced from $586,373 to $450,000 following our repayment of $136,373 in then outstanding borrowings, and as a result of the reduction in commitments, we recorded a loss on modification or early extinguishment of debt of $1,075 for the nine months ended September 30, 2023;
•the feature of our credit facility permitting us to reborrow any repaid funds was eliminated;
•we continue to have the ability to fund $400,000 of capital expenditures per year and we are restricted in our ability to acquire real property as defined in the credit agreement;
•SOFR was established as the replacement benchmark rate in place of LIBOR to calculate interest payable on amounts outstanding under our credit facility, and the interest premium under our credit facility was increased by 40 basis points; and
•we are required to repay outstanding amounts under our credit facility with excess cash flow, and certain financial covenants and restrictions on distributions to common shareholders, share repurchases, capital expenditures, acquiring additional properties and incurring additional indebtedness (in each case subject to various exceptions) will remain in place through the maturity date of our credit facility.
Pursuant to our credit agreement, we pledged certain equity interests of subsidiaries owning properties to secure our obligations under our credit agreement and have provided first mortgage liens on 62 medical office and life science properties with an aggregate net book value of $826,780 as of September 30, 2023 to secure our obligations, which pledges and/or mortgage liens may be removed or new ones may be added based on outstanding debt amounts, among other things.
Our credit agreement requires us to maintain collateral properties with an aggregate appraised value of at least $1,090,909, and allows Wells Fargo Bank, National Association, as administrative agent under our credit facility, or the Administrative Agent, to periodically reappraise the collateral properties. On June 23, 2023, the Administrative Agent notified us that the reappraised value of the then 61 medical office and life science properties securing our credit facility since September 2021 had declined from $1,337,200 to $1,046,770, below the $1,090,909 threshold required under our credit agreement. Failure to meet the required threshold constitutes a non-monetary event of default under our credit agreement. In July 2023, we obtained a limited waiver from the Administrative Agent and requisite lenders under our credit facility, which waived the event of default and decreased the required appraised value of the collateral properties through September 30, 2023. In September 2023, we pledged the equity interests of an additional subsidiary owning one medical office property to secure our obligations under our credit agreement and provided a first mortgage lien on such medical office property. As of September 30, 2023, we believe we were in compliance with this covenant.
In April 2023, we prepaid a mortgage note secured by one of our senior living communities with an outstanding principal balance of approximately $14,565, a maturity date in June 2023 and an annual interest rate of 6.64% using cash on hand.
12
DIVERSIFIED HEALTHCARE TRUST
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(dollar amounts in thousands, except per share data or as otherwise stated)
Our credit agreement and our senior unsecured notes indentures and their supplements provide for acceleration of payment of all amounts outstanding upon the occurrence and continuation of certain events of default, such as, in the case of our credit agreement, a change of control of us, as defined, which includes The RMR Group LLC, or RMR, ceasing to act as our business and property manager. Our senior unsecured notes indentures and their supplements and our credit agreement also contain covenants that restrict our ability to incur debts, including debts secured by mortgages on our properties, in excess of calculated amounts and require us to maintain various financial ratios, and our credit agreement contains covenants that restrict our ability to make distributions to our shareholders in certain circumstances. As of September 30, 2023, our ratio of consolidated income available for debt service to debt service was below the 1.5x incurrence requirement under our credit agreement and our public debt covenants as the effects of the slower than anticipated and uneven recovery of our SHOP business from the COVID-19 pandemic, wage and commodity price inflation, rising interest rates, increased insurance costs, geopolitical risks and other economic, market and industry conditions continued to adversely impact our operations. We are unable to refinance existing or maturing debt or issue new debt until this ratio is at or above 1.5x on a pro forma basis. As of September 30, 2023, we believe we were in compliance with all of the other covenants under our senior unsecured notes indentures and their supplements, our credit agreement and our other debt obligations, subject to the waivers described above. Although we continue to take steps to enhance our ability to maintain sufficient liquidity, a protracted negative impact on the economy or the industries in which our properties and businesses operate resulting from wage or commodity price inflation, rising or sustained high interest rates, increased insurance costs, geopolitical risks or other economic, market or industry conditions, including the delayed and uneven recovery of the senior housing industry, downturns or recessions, may cause increased pressure on our ability to satisfy financial and other covenants. If our operating results and financial condition are significantly negatively impacted by economic conditions or otherwise, we may fail to satisfy covenants and conditions under our credit agreement or fail to satisfy our public debt covenants. In addition, we may be unable to repay the $450,000 in outstanding borrowings under our credit facility if we do not succeed in realizing our plan to address the uncertainty of our ability to continue as a going concern or if that plan is not successful. Further, if we believe we will not be able to satisfy our financial or other covenants, we expect that we would seek waivers or amendments prior to any covenant violation or seek other financing alternatives. Any such waiver or amendment may result in increased costs and interest rates, additional restrictive covenants or other lender protections imposed on us. For example, we are currently engaging in discussions with the lenders under our credit facility regarding a possible extension and amendment of that facility, as described above.
Note 5.  Fair Value of Assets and Liabilities
The following table presents certain of our assets that are measured at fair value at September 30, 2023 and December 31, 2022, categorized by the level of inputs as defined in the fair value hierarchy under GAAP, used in the valuation of each asset.
As of September 30, 2023As of December 31, 2022
DescriptionCarrying AmountEstimated Fair ValueCarrying AmountEstimated Fair Value
Recurring Fair Value Measurements Assets:    
Investment in AlerisLife (Level 1) (1)
$— $— $5,880 $5,880 
Investment in unconsolidated joint venture (Level 3) (2)
$107,773 $107,773 $104,697 $104,697 
Investment in unconsolidated joint venture (Level 3) (3)
$45,971 $45,971 $50,780 $50,780 
Non-Recurring Fair Value Measurements Assets:
Real estate properties held for sale (Level 2) (4)
$6,586 $6,586 $— $— 
(1)On February 2, 2023, in connection with the proposed acquisition of AlerisLife Inc., or AlerisLife, by a subsidiary of ABP Trust, which is the controlling shareholder of The RMR Group Inc., or RMR Inc., we agreed to tender all of the 10,691,658 shares of common stock of AlerisLife, we owned at a price of $1.31 per share, and the acquisition was completed on March 20, 2023. Prior to March 20, 2023, these AlerisLife common shares were included in other assets, net in our condensed consolidated balance sheets, and were reported at fair value, which was based upon quoted market prices on The Nasdaq Stock Market LLC, or Nasdaq, (Level 1 inputs). During the three months ended September 30, 2022, we recorded an unrealized loss of $2,674, and during the nine months ended September 30, 2023 and 2022, we recorded an unrealized gain of $8,126 and an unrealized loss of $21,384, respectively, which are included in gains and losses on equity securities, net in our condensed consolidated statements of comprehensive income (loss), to adjust the carrying value of our former investment in AlerisLife common shares to their fair value. See Note 10 for further information about our investment in AlerisLife.
(2)The 10% equity interest we own in the Seaport JV is included in investments in unconsolidated joint ventures in our condensed consolidated balance sheet, and is reported at fair value, which is based on significant unobservable inputs
13
DIVERSIFIED HEALTHCARE TRUST
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(dollar amounts in thousands, except per share data or as otherwise stated)
(Level 3 inputs). The significant unobservable inputs used in the fair value analysis are a discount rate of 6.50%, an exit capitalization rate of 6.00%, a holding period of 10 years and market rents. The assumptions made in the fair value analysis are based on the location, type and nature of the property, and current and anticipated market conditions, which are derived from appraisers. See Note 2 for further information regarding this joint venture.
(3)The 20% equity interest we own in the LSMD JV is included in investments in unconsolidated joint ventures in our condensed consolidated balance sheet, and is reported at fair value, which is based on significant unobservable inputs (Level 3 inputs). The significant unobservable inputs used in the fair value analysis are discount rates of between 6.25% and 8.00%, exit capitalization rates of between 4.75% and 7.00%, holding periods of 10 years and market rents. The assumptions we made in the fair value analysis are based on the location, type and nature of each property, and current and anticipated market conditions, which are derived from appraisers. See Note 2 for further information regarding this joint venture.
(4)We have assets in our condensed consolidated balance sheets that are measured at fair value on a non-recurring basis. During the three months ended September 30, 2023, we recorded impairment charges of $427 to reduce the carrying value of one life science property that is classified as held for sale to its estimated sales price, less estimated costs to sell, of $5,845 under an agreement to sell that we have entered into with a third party. During the three months ended September 30, 2023, we also recorded impairment charges of $729 to reduce the carrying value of one senior living community that is classified as held for sale to its estimated sales price, less estimated costs to sell, of $741 under an agreement to sell that we have entered into with a third party. See Note 2 for further information about impairment charges and the properties we have classified as held for sale.
In addition to the assets described in the table above, our financial instruments at September 30, 2023 and December 31, 2022 included cash and cash equivalents, restricted cash, certain other assets, our credit facility, senior unsecured notes, secured debt and finance leases and certain other unsecured obligations and liabilities. The fair values of these financial instruments approximated their carrying values in our condensed consolidated financial statements as of such dates, except as follows:
 As of September 30, 2023As of December 31, 2022
Description
Carrying Amount (1)
Estimated Fair Value
Carrying Amount (1)
Estimated Fair Value
Senior unsecured notes, 4.750% coupon rate, due 2024
$249,837 $236,225 $249,628 $211,250 
Senior unsecured notes, 9.750% coupon rate, due 2025
497,019 481,350 495,710 478,985 
Senior unsecured notes, 4.750% coupon rate, due 2028
494,428 364,555 493,473 284,375 
Senior unsecured notes, 4.375% coupon rate, due 2031
493,630 346,180 492,986 317,130 
Senior unsecured notes, 5.625% coupon rate, due 2042
342,851 201,600 342,565 151,200 
Senior unsecured notes, 6.250% coupon rate, due 2046
243,555 154,700 243,338 115,300 
Secured debts (2)
13,660 12,491 30,177 28,275 
 $2,334,980 $1,797,101 $2,347,877 $1,586,515 
(1)Includes unamortized net debt issuance costs, premiums and discounts.
(2)We assumed certain of these secured debts in connection with our acquisition of certain properties. We recorded the assumed mortgage notes at estimated fair value on the date of acquisition and we are amortizing the fair value adjustments, if any, to interest expense over the respective terms of the mortgage notes to adjust interest expense to the estimated market interest rates as of the date of acquisition.
We estimated the fair values of our two issuances of senior unsecured notes due 2042 and 2046 based on the closing price on Nasdaq (Level 1 inputs) as of September 30, 2023 and December 31, 2022. We estimated the fair values of our four issuances of senior unsecured notes due 2024, 2025, 2028 and 2031 using an average of the bid and ask price on Nasdaq on or about September 30, 2023 and December 31, 2022 (Level 2 inputs as defined in the fair value hierarchy under GAAP). We estimated the fair values of our secured debts by using discounted cash flows analyses and currently prevailing market terms as of the measurement date (Level 3 inputs as defined in the fair value hierarchy under GAAP). Because Level 3 inputs are unobservable, our estimated fair values may differ materially from the actual fair values.
14
DIVERSIFIED HEALTHCARE TRUST
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(dollar amounts in thousands, except per share data or as otherwise stated)
Note 6.  Shareholders' Equity
Common Share Awards:
On June 5, 2023, in accordance with our Trustee compensation arrangements, we awarded to each of our then seven Trustees 20,000 of our common shares, valued at $1.74 per share, the closing price of our common shares on Nasdaq on that day.
On September 13, 2023, we awarded under our equity compensation plan an aggregate of 800,000 of our common shares, valued at $2.33 per share, the closing price of our common shares on Nasdaq on that day, to our officers and certain other employees of RMR.
On September 26, 2023, in accordance with our Trustee compensation arrangements, we awarded 20,000 of our common shares in connection with the election of one of our Trustees in September 2023, valued at $2.23 per share, the closing price of our common shares on Nasdaq on that day.
Common Share Purchases:
During the three and nine months ended September 30, 2023, we purchased an aggregate of 151,405 and 181,893 of our common shares, respectively, valued at a weighted average share price of $2.33 and $2.12 per common share, respectively, from our officers and certain current and former officers and employees of RMR in satisfaction of tax withholding and payment obligations in connection with the vesting of awards of our common shares.
Distributions:
During the nine months ended September 30, 2023, we declared and paid quarterly distributions to common shareholders as follows:
Declaration DateRecord DatePayment DateDistribution Per ShareTotal Distributions
January 12, 2023January 23, 2023February 16, 2023$0.01 $2,397 
April 13, 2023April 24, 2023May 18, 20230.01 2,397 
July 13, 2023July 24, 2023August 17, 20230.01 2,398 
$0.03 $7,192 
On October 12, 2023, we declared a quarterly distribution to common shareholders of record on October 23, 2023 of $0.01 per share, or approximately $2,405. We expect to pay this distribution on or about November 16, 2023.
Note 7.  Segment Reporting
We operate in, and report financial information for, the following two segments: Office Portfolio and SHOP. We aggregate each of these two reporting segments based on their similar operating and economic characteristics. Our Office Portfolio segment consists of medical office properties leased to medical providers and other medical related businesses, as well as life science properties leased to biotech laboratories and other similar tenants. Our SHOP segment consists of managed senior living communities that provide short term and long term residential living and, in some instances, care and other services for residents where we pay fees to managers to operate the communities on our behalf.
We also report “non-segment” operations, which consists of triple net leased senior living communities and wellness centers that are leased to third party operators from which we receive rents, which we do not consider to be sufficiently material to constitute a separate reporting segment, and any other income or expenses that are not attributable to a specific reporting segment.
15
DIVERSIFIED HEALTHCARE TRUST
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(dollar amounts in thousands, except per share data or as otherwise stated)
For the Three Months Ended September 30, 2023
 Office PortfolioSHOPNon-SegmentConsolidated
Revenues:    
Rental income$55,058 $— $8,332 $63,390 
Residents fees and services— 293,134 — 293,134 
Total revenues55,058 293,134 8,332 356,524 
Expenses:    
Property operating expenses25,784 272,445 203 298,432 
Depreciation and amortization20,175 44,587 2,474 67,236 
General and administrative— — 6,954 6,954 
Acquisition and certain other transaction related costs
— — 3,676 3,676 
Impairment of assets427 729 — 1,156 
Total expenses46,386 317,761 13,307 377,454 
Interest and other income— 115 3,128 3,243 
Interest expense(119)(79)(47,560)(47,758)
Income (loss) before income tax expense and equity in net losses of investees8,553 (24,591)(49,407)(65,445)
Income tax expense— — (189)(189)
Equity in net losses of investees(145)— — (145)
Net income (loss)$8,408 $(24,591)$(49,596)$(65,779)
16
DIVERSIFIED HEALTHCARE TRUST
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(dollar amounts in thousands, except per share data or as otherwise stated)
 For the Nine Months Ended September 30, 2023
 Office PortfolioSHOPNon-SegmentConsolidated
Revenues:    
Rental income$165,448 $— $25,753 $191,201 
Residents fees and services— 857,572 — 857,572 
Total revenues165,448 857,572 25,753 1,048,773 
Expenses:    
Property operating expenses73,237 796,733 770 870,740 
Depreciation and amortization63,065 129,891 7,474 200,430 
General and administrative— — 20,111 20,111 
Acquisition and certain other transaction related costs
— — 9,812 9,812 
Impairment of assets14,034 4,346 — 18,380 
Total expenses150,336 930,970 38,167 1,119,473 
Gain on sale of properties— 1,233 — 1,233 
Gains on equity securities, net— — 8,126 8,126 
Interest and other income— 1,581 10,991 12,572 
Interest expense(344)(502)(142,076)(142,922)
Loss on modification or early extinguishment of debt— — (1,075)(1,075)
Income (loss) before income tax expense and equity in net earnings of investees14,768 (71,086)(136,448)(192,766)
Income tax expense— — (379)(379)
Equity in net earnings of investees2,137 — — 2,137 
Net income (loss)$16,905 $(71,086)$(136,827)$(191,008)
Under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, the U.S. Department of Health and Human Services established a Provider Relief Fund. Subsequently, the American Rescue Plan Act, or ARPA, was enacted. Retention and use of the funds received under the CARES Act and ARPA are subject to certain terms and conditions. The terms and conditions require that the funds be utilized to compensate for lost revenues that are attributable to the COVID-19 pandemic and for eligible costs to prevent, prepare for and respond to the COVID-19 pandemic that are not covered by other sources. Further, fund recipients are required to be participating in Medicare at the time of distribution and are subject to certain other terms and conditions, including quarterly reporting requirements. In addition, fund recipients are required to have billed Medicare during 2019 and to continue to provide care after January 31, 2020 for diagnosis, testing or care for individuals with possible or actual COVID-19 cases. Any funds not used in accordance with the terms and conditions must be returned. We recognize income from government grants on a systematic and rational basis over the period in which we recognize the related expenses or loss of revenues for which the grants are intended to compensate when there is reasonable assurance that we will comply with the applicable terms and conditions of the grant and there is reasonable assurance that the grant will be received. We have received funds related to certain programs under the CARES Act, ARPA and various state programs in which certain of our communities in our SHOP segment are located. We have recognized $1,581 and $1,084 with respect to those funds we received as interest and other income in our condensed consolidated statements of comprehensive income (loss) with respect to our SHOP segment for the nine months ended September 30, 2023 and 2022, respectively.
 As of September 30, 2023
 Office PortfolioSHOP Non-SegmentConsolidated
Total assets$1,918,452 $3,132,120 $479,684 $5,530,256 
17
DIVERSIFIED HEALTHCARE TRUST
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
(dollar amounts in thousands, except per share data or as otherwise stated)
 For the Three Months Ended September 30, 2022
 Office PortfolioSHOPNon-SegmentConsolidated
Revenues:    
Rental income$55,254 $— $8,706 $63,960 
Residents fees and services— 258,960 — 258,960 
Total revenues55,254 258,960 8,706 322,920 
Expenses:    
Property operating expenses24,179 264,722 195 289,096 
Depreciation and amortization19,037 38,484 2,886 60,407 
General and administrative— — 6,179 6,179 
Acquisition and certain other transaction related costs
— — 289 289 
Total expenses43,216 303,206 9,549 355,971 
(Loss) gain on sale of properties(5,074)30 — (5,044)
Losses on equity securities, net— — (2,674)(2,674)
Interest and other income— 125 3,974 4,099 
Interest expense(217)(298)(46,421)(46,936)
Income (loss) before income tax expense and equity in net earnings of investees6,747 (44,389)(45,964)(83,606)
Income tax expense— — (13)(13)
Equity in net earnings of investees2,127 — — 2,127 
Net income (loss)$8,874 $(44,389)$(45,977)$(81,492)
 For the Nine Months Ended September 30, 2022
 Office PortfolioSHOP Non-SegmentConsolidated
Revenues:    
Rental income$162,861 $— $28,906 $191,767 
Residents fees and services— 754,914 — 754,914 
Total revenues162,861 754,914 28,906 946,681 
Expenses:    
Property operating expenses69,652 754,057 195 823,904 
Depreciation and amortization55,424 111,836 8,667 175,927 
General and administrative— — 20,671 20,671 
Acquisition and certain other transaction related costs
— — 1,826 1,826 
Total expenses125,076 865,893 31,359 1,022,328 
Gain on sale of properties321,242 822 — 322,064 
Losses on equity securities, net— — (21,384)(21,384)
Interest and other income— 1,084 5,676 6,760 
Interest expense(798)